Left Ventricle Diastolic Function in Patients Underwent Chemotherapy with Doxorubicin

  • Januar Wibawa Martha Department of Cardiology and Vascular Medicine, Medical Faculty, University of Padjadjaran Dr. Hasan Sadikin Hospital, Bandung, West Java
  • Sunarya Surianata Department of Cardiology and Vascular Medicine, Faculty of Medicine - University of Indonesia National Cardiac Center, Harapan Kita, Jakarta
  • Amiliana M Soesanto Department of Cardiology and Vascular Medicine, Faculty of Medicine - University of Indonesia National Cardiac Center, Harapan Kita, Jakarta

Abstract

Background. Doxorubicin is one of the first-line chemoterapy against many form of neoplasm but the use is hampered by its cardiotoxic poten-tial with the end result of congestive heart failure. It is imperative that specific monitoring scheme is applied to detect as early as possible the cardiac damage due to doxorubicin. There is large body of evidence that left ventricular diastolic dysfunction precede systolic dysfunction. There-fore, diastolic function may serve as am early monitoring parameter in patients receiving doxorubicin. This study is aimed to delineate the preva-lence of diastolic dysfunction among patients receiving doxorubicin, to define the lowest cumulative dosage of doxorubicin that already cause di-astolic dysfunction, and to describe the association between cumulative dosage of doxorubicin with grade of diastolic dysfunction.
Methods. This study utilizes cross sectional design, conducted in Depart-ment of Cardiology and Vascular Medicine to 38 cancer patients receiving doxorubicin in Subdivision of Hematology-Oncology Department of Inter-nal Medicine, Faculty of Medicine, Padjadjaran University. The study com-menced from September 2006 until January 2007.
Results. The prevalence of diastolic dysfunction among patients who re-ceived doxorubicin is 86,8%. The actual lowest cumulative dose of doxoru-bicin that already had diastolic dysfunction is 112 mg/m2 but the crossing point between correlation line and the occurrence of E/A ratio and Em/Am ratio of less than 1 is between 110-130 mg/m2. There is negative correlation between cumulative dose of doxorubicin and E/A ratio (r = -0,62) and Em/Am ratio (r = -0,69). Cumulative dose of doxorubicin among normal dias-tolic function, grade 1 diastolic dysfunction and grade 2 diastolic dysfunction are 101,4 + 3,9 mg/m2 , 168,3 + 7,6 mg/m2 and 237,1 + 11 mg/m2, respec-tively (p < 0,01). There is positive correlation between cumulative dose of doxorubicin with grade of diastolic dysfunction (r = 0,7)
Conclusions. The prevalence of diastolic dysfunction among patients who received doxorubicin is 86,8%. The lowest cumulative dose of doxorubi-cin that already had diastolic dysfunction is between 110-130 mg/m2 . There is a strong positive correlation between cumulative dose of doxorubicin with grade of diastolic dysfunction.

Downloads

Download data is not yet available.

References

Shan K, Lincoff MI and Young JB. Anthracycline-Induced Cardiotoxicity. Ann Intern Med 1996;125(1): 47-58

Zile M, Brutsaert D. New concepts in diastolic dysfunction and diastolic heart failure I: diagnosis, prognosis, and measurements of diastolic function. Circulation2002; 105: 1387-93.

Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992; 20:62-9.

Antman E, Smith SC, Alpert JS, Gregoratos G, Anderson J, Hiratzka LH, Faxon DP et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography. Circulation. 2003;108:000-000.

Klocke FJ, Baird MG, Lorell BH, Bateman TJ, Messer JV, Berman DS et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice. Circulation2003;108:0000–0000.

Schuchter LM, Hensley ML, Meropol NJ, and Winer EP. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20(12);2895-2903

Powis G. Toxicity of free radical forming anticancer agent. The toxicity of anticancer drugs. Pergmon press. 1991 : 106-19

Yeh ETH, Tong T, Lenihan DJ, et al. Cardiovascular complication of cancer therapy, diagnosis, pathogenesis, and management. Circulation2004 ; 109 : 122-31

Kremer LCM, van der Pal HJH, Offringa M, van Dalen EM and Voûte PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology 13: 819–829, 2002

Mancini DM, Beniaminovitz A. Myocarditis and specific cardiomiopathies. Dalam : Fuster V, Alexander RW, O’Rourke RA eds. Hurst’s the heart. 10 th ed. McGraw-Hill, 2001 :2021-2

Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, binded, long-term observational study of outcome in 120 patients. Ann Oncol2002; 13: 699–709

Singl PK, Illiskovic N. Doxorubicin induced cardiomyopathy. N Engl J Med1998 ; 339 : 900 – 5

Acker SABE, Kramer K, Voest EE et al. Doxorubicin induced cardiotoxicity monitored by ECG. Eur J Pediatrics1998 ; 157 : 464-7

Thigpen JT. Innovations in anthracycline therapy: An overview. Comm Oncol 2005; 2 : 3-7

Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer : the role of diastolic function. Heart 2004 ;90 : 1214-6

Zhu W, Zou Y, Aikw R ,et al. MAPK superfamily play an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation1999 ; 100 : 2100-07

Lipshultz SE, Rifi N, Dlton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin treated children with acute lymphoblstic leukemia. N Engl J Med2004 ; 351 : 145-53

Hellmann K. Preventing the cardiotoxicity of anthracycline by dexrazoxane. BMJ1999 ; 319 : 1085-6

Hashimoto I, Ichida F, Miura M, et al. Automatic border detection identifies subclinical anthracycline cardiotoxicity in children with malignancy. Circulation1999 ; 99 : 2367-70

Schwartz CL, Hobbie WL, Truesdell S, Constine LC, and Clark EB. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol1993 ; 11:1906-1910.

Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol1998 ; 16 : 545-50

Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992; 20:62-9.

Hausdorf G, Morf G, Beron G, Erttmann R, Winkler K, Landbeck G, Keck EW. Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. Br Heart J. 1988 ; 60(4) : 309-15.

Cottin Y, Touzery C, Coudert B, Gilles A, Walker A, Massing JL, Toubeau M, et al. Impairment of diastolic function during short-term anthracycline chemotherapy. Br Heart J 1995 ; 73 :61-64

Schmitt K, Tulzer G, Merl M, Aichhorn G, Grillenberger A, Wiesinger G, Hofstadler G. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: Diastolic versus systolic parameters. Eur J Pediatrics1995 ; 154(3) : 201 - 204

Nishimura RA, Tajik AJ. Evaluation of diastolic filling ofleft ventricle in healt and disease : doppler echocardiography is the clinician’s rosseta stone. J Am Coll Cardiol1997; 30:8-18.

Garcia MJ, Thomas JD, Klein A. New doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32:865-875.
Views & Downloads
Abstract views: 571   
PDF (Bahasa Indonesia) downloads: 386   
How to Cite
Martha, J., Surianata, S., & Soesanto, A. (1). Left Ventricle Diastolic Function in Patients Underwent Chemotherapy with Doxorubicin. Indonesian Journal of Cardiology, 28(5), 320-326. https://doi.org/10.30701/ijc.v28i5.217
Section
Clinical Research